UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
 

 
FORM 8-K
 

 
CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): October 31, 2017
 

Edge Therapeutics, Inc.
(Exact name of Registrant as specified in its charter)
 


Delaware
001-37568
26-4231384
(State or Other Jurisdiction
of Incorporation or Organization)
(Commission
File Number)
(I.R.S. Employer
Identification No.)

300 Connell Drive, Suite 4000
Berkeley Heights, NJ 07922
(800) 208-3343
(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)

Not Applicable
(Former name or former address, if changed since last report)
 

 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

                 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

                 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)

                 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

                 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 


Item 2.02            Results of Operations and Financial Condition

On November 1, 2017, Edge Therapeutics, Inc. issued a press release announcing its financial results for the three months ended September 30, 2017. A copy of that press release and the financial schedules attached thereto is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.

In accordance with General Instruction B.2 of Form 8-K, the information set forth under Item 2.02 (including Exhibit 99.1) of this Current Report on Form 8-K is deemed to be “furnished” and shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”).   The information in this Item 2.02, as well as Exhibit 99.1, shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act regardless of any general incorporation language in such filing.

Item 5.02   Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(c)

Appointment of Andrew Saik as Chief Financial Officer

The Board of Directors (the “ Board ”) of Edge Therapeutics, Inc. (the “ Edge ”) has appointed Andrew Saik, 48, to the position of Chief Financial Officer, effective as of October 31, 2017 (the “ Appointment Date ”). Mr. Saik replaces Albert N. Marchio, II who has acted as Edge’s Chief Accounting and Administrative Officer and Chief Financial Officer on an interim basis since March 10, 2016.  Mr. Marchio has resigned as Edge’s interim Chief Financial Officer and will continue his role as Edge’s Chief Accounting and Administrative Officer on the Appointment Date.

Mr. Saik most recently served as Chief Financial Officer of Vertice Pharma from November 2015 to July 2017.  Mr. Saik served as Senior Vice President, Finance and Treasurer at Auxilium Pharmaceuticals Inc. (f/k/a Endo Health Solutions Inc.) (“ Auxilium ”) from August 2014 to January 2015, where he was responsible for internal and external reporting, global consolidations of M&A transactions, cash management, debt financing and risk management. During his tenure at Auxilium, he helped complete the $1.6 billion acquisition of Paladin Labs and refinance $3 billion in debt in a new corporate structure.  Prior to Auxilium, Mr. Saik served in senior financial management roles with progressive responsibility at Valeant Pharmaceuticals International (f/k/a ICN Pharmaceuticals Inc.) (“ Valeant ”) from January 2001 to July 2002, most recently as its Senior Vice President, Finance.  In this post, he served as the overall finance lead for the acquisition and integration of the Johnson & Johnson and Sanofi-Aventis dermatology business units in the U.S. and Canada, enabling Valeant to build the largest dermatology business in North America. Previously at Valeant, he was Chief Financial Officer of the $1.5 billion Specialty Pharmaceuticals Division which included the U.S., Canada and Australia. Earlier in his career, Mr. Saik was a finance manager and analyst at Nexgenix, Inc. from October 1999 to January 2001 and the Atlantic Richfield Corporation from June 1996 to October 1999. He holds a Master of Business Administration from the University of Southern California and a Bachelor of Arts from the University of California, Los Angeles.

In connection with his appointment, Edge entered into an at-will Executive Employment Agreement with Mr. Saik as Chief Financial Officer (the “ Employment Agreement ”), Mr. Saik will receive an annual salary of $370,000, which may be increased, decreased or stay the same, depending on Mr. Saik’s performance and the performance of Edge (the “ Base Salary ”).

Under his Employment Agreement, Mr. Saik is eligible to earn an annual discretionary performance-based bonus, with a target bonus opportunity equal to 45% of the Base Salary, as determined by the Board or the Compensation Committee of the Board (the “ Compensation Committee ”); provided that Mr. Saik remains employed with Edge on the last day of the relevant performance period. During his employment, Mr. Saik will be eligible to be granted equity awards by Edge, as may be determined by the Board or the Compensation Committee.

The Employment Agreement may be terminated by Edge with or without Cause, one the one hand, or by Mr. Saik with or without Good Reason or upon his death or termination by reason of a Disability, on the other hand (as these terms are defined in the Employment Agreement).  In the event that Mr. Saik’s employment is terminated (a) by Edge other than for Cause, death or Disability or (b) upon his resignation with Good Reason, Mr. Saik will be entitled to certain severance payments and benefits, including an amount equal to his Base Salary plus (i) certain Accrued Obligations through the Date of Termination (as these terms are defined in the Employment Agreement) and (ii) 12 months of COBRA premium reimbursement in exchange for his execution of a release of claims against Edge.


Under the Employment Agreement, Mr. Saik is also entitled to participate in the employee benefit plans, policies, practices and arrangements and is eligible for the same number of holidays and vacation days, in each case as are generally allowed to other similarly situated executives of Edge.

The foregoing summary of the Employment Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Employment Agreement, which is attached as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

(e)

Equity Grant to Andrew Saik

The Compensation Committee granted Mr Saik non-qualified stock options to purchase 200,000 shares of Edge’s common stock pursuant to the inducement grant exception under NASDAQ Rule 5635(c)(4) and not pursuant to Edge’s 2014 Equity Incentive Plan or any other equity incentive plan of Edge (the “ Options ”). The grant is effective as of November 1, 2017 (“ Grant Date ”). The Options were granted as an inducement material to Mr. Saik’s acceptance of employment with Edge.

The Options have an exercise price equal to the closing price of Edge’s common stock on the closing price of Edge’s common stock as reported by NASDAQ on the Grant Date.  The Options will vest over a period of 4 years, with 25% vesting on October 31, 2018, which is one year following Mr. Saik’s date of hire and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service to Edge through each vesting date and subject to acceleration or forfeiture upon the occurrence of certain events as set forth in Mr. Saik’s option agreement.

Item 8.01   Other Events.

On November 1, 2017, Edge issued a press release announcing the financial results for the third quarter ended September 30, 2017 and the appointment of Mr. Saik as Chief Financial Officer. A copy of the press release is filed herewith as Exhibit 99.1.
 
Item 9.01.   Financial Statements and Exhibits

Exhibit
Number
 
Description
10.1
 
Executive Employment Agreement by and between Andrew Saik and Edge entered into as of October 31, 2017.
     
99.1
 
Press release dated November 1, 2017.
 

EXHIBIT INDEX

Exhibit
Number
 
Description
 
Executive Employment Agreement by and between Andrew Saik and Edge entered into as of October 31, 2017.
     
 
Press release dated November 1, 2017.
 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Dated: November 1 , 2017
Edge Therapeutics, Inc.
       
 
By:
/s/ Albert N. Marchio II
   
Name:
Albert N. Marchio II
   
Title:
Chief Accounting and Administrative Officer
 




Exhibit 10.1
 
EXECUTIVE EMPLOYMENT AGREEMENT
 
This Executive Employment Agreement (the “Agreement”) is entered into as of October 31, 2017 (the “Effective Date”) by and between Edge Therapeutics, Inc., a Delaware corporation (the “Company”), and Andrew Saik (“Executive”).
 
W   I   T   N   E   S   S   E   T   H  :
 
WHEREAS, the Company desires to employ Executive and Executive desires to be employed by the Company, in each case, subject to the terms and provisions of this Agreement.
 
NOW, THEREFORE, in consideration of the promises and mutual covenants contained herein and for other good and valuable consideration, the receipt and sufficiency of which are mutually acknowledged, the Company and Executive hereby agree as follows:
 
Section 1.                      Definitions .
 
(a)            Accrued Obligations ” shall mean (i) all accrued but unpaid Base Salary through the Date of Termination, (ii) any unpaid or unreimbursed business expenses incurred in accordance with Section 6 hereof, (iii) any accrued but unused vacation time through the Date of Termination, (iv) any earned but unpaid annual bonus with respect to the year immediately preceding the year in which the Date of Termination occurs and (v) all vested benefits (including, if applicable, equity awards) in accordance with the terms of the governing documents.
 
(b)            Base Salary ” shall mean the salary provided for in Section 4(a) hereof, as adjusted from time to time.
 
(c)            Board ” shall mean the Board of Directors of the Company.
 
(d)            Confidentiality and Invention Assignment Agreement ” shall mean the Employee Confidentiality and Invention Assignment Agreement, executed by the Company and Executive and attached hereto as Exhibit A .
 
(e)            Cause ” shall mean (i) Executive’s failure, neglect, or refusal to perform in any material respect Executive’s duties and responsibilities under this Agreement (in each case, except where due to a Disability, sickness or illness) ; (ii) any act of Executive that has, or could reasonably be expected to have, the effect of injuring the business of the Company or its subsidiaries in any material respect; (iii) Executive’s conviction of, or plea of guilty or no contest to: (x) a felony or (y) any other criminal charge that has, or could be reasonably expected to have, an adverse impact on the performance of Executive’s duties to the Company or otherwise result in material injury to the reputation or business of the Company or any of its subsidiaries; (iv) Executive’s commission of an act of fraud or embezzlement against the Company or any of its subsidiaries; (v) any material violation by Executive of the policies of the Company, including but not limited to those relating to sexual harassment or business conduct, and those otherwise set forth in the manuals or statements of policy of the Company, as may be amended from time to time; (vi) Executive’s material violation of federal or state securities laws; or (vii) Executive’s material breach of this Agreement or material breach of the Confidentiality and Invention Assignment Agreement.
1

(f)            Code ” shall mean the Internal Revenue Code of 1986, as amended, and the rules and regulations promulgated thereunder.
 
(g)            Date of Termination ” shall mean the date on which Executive’s employment terminates.
 
(h)            Disability ” shall mean any physical or mental disability or infirmity of Executive that prevents Executive from performing Executive’s duties with or without a reasonable accommodation for a period of (i) ninety (90) consecutive days or (ii) one hundred twenty (120) non-consecutive days during any twelve (12) month period.  Any question as to the existence, extent, or potentiality of Executive’s Disability upon which Executive and the Company cannot agree shall be determined by a qualified, independent physician selected by the Company and approved by Executive (which approval shall not be unreasonably withheld).  The determination of any such physician shall be final and conclusive for all purposes of this Agreement.  Executive understands that Executive is a “key employee” in connection with any leave qualifying for coverage under the Family and Medical Leave Act (“FMLA”).
 
(i)            Good Reason ” shall mean, without Executive’s written consent, (i) a material diminution in Executive’s title, duties, or responsibilities as set forth in Section 3 hereof; (ii) a material reduction in Base Salary as set forth in Section 4(a) hereof (other than pursuant to a reduction applicable to all similarly situated executives); (iii) any material breach of this Agreement by the Company (other than a provision that is covered by clause (i) or (ii))   or (iv) the Company’s requiring Executive to be primarily based at any office or location outside of a twenty-five (25) mile radius of 300 Connell Drive, Berkeley Heights, NJ 07922 (provided that such relocation materially increases Executive’s commute), except for travel reasonably required in the performance of Executive’s responsibilities.  Notwithstanding the foregoing, in the event that the Company reasonably believes that Executive may have engaged in conduct that could constitute Cause hereunder, the Company may, in its sole and absolute discretion, suspend Executive’s duties or employment, and in no event shall any such suspension constitute an event pursuant to which Executive may terminate employment with Good Reason or otherwise constitute a breach of this Agreement by the Company; provided , that no such suspension shall alter the Company’s obligations under this Agreement during such period of suspension.
 
(j)            Release of Claims ” shall mean a separation agreement in a form acceptable to the Company under which Executive releases the Company and certain other persons and entities from any and all claims and causes of action and the execution of which is a condition precedent to Executive’s eligibility for the payments and benefits described in Sections 7(d) and 7(e).
 
(k)            Severance Benefits ” shall mean continued payment of Base Salary during the Severance Term, in accordance with the Company’s regular payroll practices.
 
(l)            Severance Term ” shall mean the twelve (12) month period, which commences on the first pay day that is at least thirty-five (35) days after the Date of Termination following termination of Executive’s employment by the Company without Cause or by Executive for Good Reason.
2

Section 2.                      Acceptance and Term .
 
The Company agrees to employ Executive on an at-will basis, and Executive agrees to accept such employment and serve the Company, in accordance with the terms and conditions set forth herein.  The term of employment (referred to herein as the “Term”) shall commence on the Effective Date and shall continue until terminated by either party at any time, subject to the provisions herein.
 
Section 3.                      Position, Duties, and Responsibilities; Place of Performance .
 
(a)            Position, Duties and Responsibilities . During the Term, Executive shall be engaged to serve as the Chief Financial Officer of the Company (together with such other position or positions consistent with Executive’s title or as the Company shall specify from time to time) and shall have such duties and responsibilities as are commensurate therewith and such other duties as may be assigned and/or prescribed from time to time by Executive’s supervisor and/or the Board.  Executive shall report to the President and Chief Executive Officer of the Company.
 
(b)            Performance . Executive shall devote Executive’s full business time, attention, skill, and best efforts to the performance of Executive’s duties under this Agreement and shall not engage in any other business or occupation during the Term, including, without limitation, any activity that (x) conflicts with the interests of the Company, (y) interferes with the proper and efficient performance of Executive’s duties for the Company, or (z) interferes with Executive’s exercise of judgment in the Company’s best interests.  Notwithstanding the foregoing, nothing herein shall preclude Executive from (i) serving, with the prior written consent of the Board, as a member of the boards of directors or advisory boards (or their equivalents in the case of a non-corporate entity) of non-competing businesses and charitable organizations, (ii) engaging in charitable activities and community affairs, and (iii) managing Executive’s personal investments and affairs; provided, however , that the activities set out in clauses (i), (ii), and (iii) shall be limited by Executive so as not to interfere, individually or in the aggregate, with the performance of Executive’s duties and responsibilities hereunder.  Executive represents that, attached hereto as Exhibit B , is a comprehensive list of all outside professional activities with which Executive is currently involved or reasonably expects to become involved.  Company hereby acknowledges that Executive’s participation in the foregoing activities at the participation levels as of the Effective Date is permitted under this paragraph, provided that the same do not interfere, individually or in the aggregate, with the performance of Executive’s duties and responsibilities hereunder.  In the event that, during Executive’s employment by the Company, Executive desires to engage in other non-competitive outside professional activities, not included on such list, Executive will first seek written approval from the President and Chief Executive Officer and such approval shall not be unreasonably withheld.
3

Section 4.                      Compensation .
 
(a)            Base Salary . During the Term, in exchange for Executive’s satisfactory performance of Executive’s duties and responsibilities Executive will initially be paid a Base Salary at the rate of $370,000 per annum, payable in accordance with the Company’s regular salary payment schedule and subject to applicable taxes and withholdings.  The Base Salary of the Executive for subsequent years of this Agreement may be increased, decreased, or may stay the same, depending on the Executive’s performance and the performance of the Company.
 
(b)            Annual Bonus . In addition to Executive’s Base Salary, during the Term, Executive will be eligible to earn an annual discretionary performance-based bonus, with a target bonus opportunity equal to 45% of the Base Salary.  Performance metrics with respect to said bonus will be determined by the Board or the compensation committee of the Board.  Executive shall be eligible for said bonus only if Executive is employed on the last day of the performance period.  Any earned annual bonus will be paid by March 15 th of the year following the year in which the applicable performance period ends.  Executive shall not be entitled to a bonus for calendar year 2017.
 
(c)            Equity Awards . During the Term, Executive shall be eligible to be granted equity awards by the Company, as determined by the Board or the compensation committee of the Board, in its sole discretion.
 
Section 5.                      Executive Benefits .
 
During the Term, Executive shall be offered participation in health insurance and other benefits provided generally to similarly situated executives of the Company, subject to the terms, conditions and eligibility requirements of the applicable benefit plans (which shall govern).  Executive shall be eligible for the same number of holidays and vacation days as well as any other benefits, except those excluded herein, in each case, as are generally allowed to similarly situated executives of the Company in accordance with the Company policy as in effect from time to time.  Nothing contained herein shall be construed to limit the Company’s ability to amend, suspend, or terminate any benefit plan or policy at any time without providing Executive notice, and the right to do so is expressly reserved.
 
Section 6.                      Reimbursement of Business Expenses .
 
During the Term, the Company shall reimburse Executive for documented, out-of-pocket business expenses reasonably incurred by Executive in the course of performing Executive’s duties and responsibilities hereunder, which are consistent with the Company’s policies in effect from time to time with respect to business expenses, and subject to the Company’s requirements with respect to reporting of such expenses.
 
Section 7.                      Termination of Employment .
 
(a)            General . Executive’s employment with the Company, and the Term, shall terminate upon the earliest to occur of: (i) Executive’s death, (ii) a termination by reason of a Disability, (iii) a termination by the Company with or without Cause, or (iv) a termination by Executive with or without Good Reason.  Notwithstanding anything herein to the contrary, the payment (or commencement of a series of payments) hereunder of any nonqualified deferred compensation (within the meaning of Section 409A of the Code) upon a termination of employment shall be delayed until such time as Executive has also undergone a “separation from service” as defined in Treas. Reg. 1.409A-1(h), at which time such nonqualified deferred compensation (calculated as of the date of Executive’s termination of employment hereunder) shall be paid (or commence to be paid) to Executive on the schedule set forth in this provision as if Executive had undergone such termination of employment (under the same circumstances) on the date of Executive’s ultimate “separation from service.”
4

(b)            Termination Due to Death or Disability . Executive’s employment under this Agreement shall terminate automatically upon Executive’s death.  Executive’s employment may be terminated by the Company, in its sole discretion, upon the occurrence of a Disability, with such termination to be effective upon Executive’s receipt of written notice of such termination.  In the event of Executive’s termination as a result of Executive’s death or Disability, Executive or Executive’s estate or beneficiaries, as the case may be, shall be entitled only to the Accrued Obligations, and Executive shall have no further rights to or interest in any compensation or any other benefits under this Agreement.
 
(c)            Termination by the Company with Cause .
 
(i)
The Company may terminate Executive’s employment at any time with Cause, effective upon Executive’s receipt of written notice of such termination; provided, however, that with respect to any Cause termination relying on clause (i), (ii), (v) or (vii) of the definition of Cause set forth in Section 1(e) hereof, to the extent that such act or acts or failure or failures to act are curable, Executive shall be given ten (10) days’ written notice by the Company of its intention to terminate him with Cause, such notice to state the act or acts or failure or failures to act that constitute the grounds on which the proposed termination with Cause is based, and such termination shall be effective at the expiration of such ten (10) day notice period unless Executive has fully cured such act or acts or failure or failures to act, to the Company’s complete satisfaction.
 
(ii)
In the event that the Company terminates Executive’s employment with Cause, Executive shall be entitled only to the Accrued Obligations (disregarding, for this purpose, clauses (iii) and (iv) of Section 1(a)).  Following such termination of Executive’s employment with Cause, except as set forth in this Section 7(c)(ii), Executive shall have no further rights to or interest in any compensation or any other benefits under this Agreement or otherwise.  For the avoidance of doubt, Executive’s sole and exclusive remedy upon a termination of employment by the Company with Cause shall be receipt of the Accrued Obligations (disregarding, for this purpose, clauses (iii) and (iv) of Section 1(a)).
 
(iii)
If Executive is terminated for Cause, Executive shall not be entitled to compensation for any accrued, but unused vacation days.
5

(d)            Termination by the Company without Cause . The Company may terminate Executive’s employment at any time without Cause, given 60 days’ notice (or pay in lieu thereof).  In the event that, during the Term, Executive’s employment is terminated by the Company without Cause (other than due to death or Disability), Executive shall be eligible for the Accrued Obligations and, provided that Executive fully executes (and does not revoke) the Release of Claims as described in Section 7(g), Executive shall also be eligible for (i) the Severance Benefits and (ii) reimbursement for Executive’s (and Executive’s eligible dependents’) health care continuation (COBRA) premiums for 12 months following such termination (provided that (A) such COBRA benefits shall not be provided beyond the date on which Executive obtains comparable coverage from a subsequent employer and (B) such benefits shall not be provided to the extent that the Company determines that it would result in any fine, penalty or violation of law for being a discriminatory benefit or otherwise) (the “ COBRA Benefits ”).  Notwithstanding the foregoing, the Severance Benefits and the COBRA Benefits shall immediately terminate, and the Company shall have no further obligations to Executive with respect thereto, and any Severance Benefits and COBRA Benefits that were provided will be reimbursed or repaid promptly by Executive to the Company, in the event that Executive breaches any provision of the Confidentiality and Invention Assignment Agreement or the Release of Claims.  Any such termination, reimbursement or repayment of Severance Benefits or COBRA Benefits shall have no effect on the Release of Claims or any of Executive’s post-employment obligations to the Company.  Following termination of Executive’s employment by the Company without Cause, except as set forth in this Section 7(d), Executive shall have no further rights to any compensation or any other benefits under this Agreement. For the avoidance of doubt, Executive’s sole and exclusive remedy upon a termination of employment by the Company without Cause shall be receipt of the Severance Benefits and the COBRA Benefits, subject to Executive’s execution and non-revocation of the Release of Claims, and the Accrued Obligations.
 
(e)            Termination by Executive with Good Reason . Executive may terminate Executive’s employment with Good Reason by providing the Company ninety (90) days’ written notice setting forth in reasonable specificity the event that constitutes Good Reason, which written notice, to be effective, must be provided to the Company within thirty (30) days after the occurrence of such event.  During such ninety (90) day notice period, the Company shall have a cure right (if curable), and if not cured within such period, Executive’s termination will be effective upon the expiration of such cure period, and in the event of such termination during the Term, Executive shall be entitled to the same payments and benefits as provided in Section 7(d) hereof for a termination by the Company without Cause, subject to the same conditions on payment and benefits (and forfeiture and repayment) as described in Section 7(d) hereof.  Following such termination of Executive’s employment by Executive with Good Reason, except as set forth in this Section 7(e), Executive shall have no further rights to any compensation or any other benefits under this Agreement.  For the avoidance of doubt, Executive’s sole and exclusive remedy upon a termination of employment with Good Reason shall be receipt of the Severance Benefits and the COBRA Benefits, subject to Executive’s execution and non-revocation of the Release of Claims, and the Accrued Obligations.
 
(f)            Termination by Executive without Good Reason . Executive may terminate Executive’s employment without Good Reason by providing the Company ninety (90) days’ written notice of such termination.  In the event of a termination of employment by Executive under this Section 7(f), Executive shall be entitled only to the Accrued Obligations (disregarding, for this purpose, clauses (iii) and (iv) of Section 1(a)).  In the event of a termination of Executive’s employment under this Section 7(f), the Company may, in its sole and absolute discretion, by written notice, accelerate the Date of Termination without changing the characterization of such termination as a termination by Executive without Good Reason (and no severance pay, notice pay or pay in lieu of notice or similar pay shall be owed to Executive).  Following such termination of Executive’s employment by Executive without Good Reason, Executive shall have no further rights to or interest in any compensation or any other benefits under this Agreement.  If Executive terminates Executive’s employment without Good Reason, Executive shall not be entitled to compensation for any accrued, but unused vacation days.  For the avoidance of doubt, Executive’s sole and exclusive remedy upon a termination of employment by Executive without Good Reason shall be receipt of the Accrued Obligations (disregarding, for this purpose, clauses (iii) and (iv) of Section 1(a)).
6

(g)            Release of Claims . Notwithstanding any provision herein to the contrary, the provision of severance benefits pursuant to subsection (d) or (e) of this Section 7 (other than the Accrued Obligations) shall be conditioned upon Executive’s execution, delivery to the Company, and non-revocation of the Release of Claims (and the expiration of any revocation period contained in such Release of Claims), such that the Release of Claims becomes effective, with all revocation periods having expired unexercised, within sixty (60) days after the Date of Termination.  If Executive fails to execute the Release of Claims in such a timely manner, or timely revokes Executive’s execution of the Release of Claims following its execution, Executive shall not be entitled to any of the severance benefits under Sections 7(d) or 7(e) (other than the Accrued Obligations).  Notwithstanding the foregoing, if such sixty (60) day period ends in a calendar year after the calendar year in which Executive’s employment terminates, then, to the extent required by Section 409A of the Code, any payment of any amount or provision of any benefit under Sections 7(d) or 7(e) or otherwise that would have been made during the calendar year in which Executive’s employment terminates shall instead be withheld and paid on the first payroll date in the calendar year after the calendar year in which Executive’s employment terminates, after which any remaining severance benefits shall thereafter be provided to Executive according to the applicable schedule set forth herein as if no such delay had occurred.
 
Section 8.                      Confidentiality and Invention Assignment Agreement; Cooperation .
 
(a)            Confidentiality and Invention Assignment Agreement . As a condition to Executive’s employment with the Company, Executive has entered into the Confidentiality and Invention Assignment Agreement.  The terms and conditions of the Confidentiality and Invention Assignment Agreement are incorporated herein by reference and the obligations and responsibilities set forth therein shall survive the termination of Executive’s employment regardless of the reason for the termination.
 
(b)            Litigation and Regulatory Cooperation . During and after Executive’s employment, Executive shall cooperate fully with the Company in the defense or prosecution of any claims or actions now in existence or which may be brought in the future against or on behalf of the Company or any of its subsidiaries which relate to events or occurrences that transpired while the Company employed Executive, provided that the Executive will not have an obligation under this paragraph with respect to any claim in which the Executive has filed directly against the Company or related persons or entities or the Company has filed directly against Executive.  The Executive’s full cooperation in connection with such claims or actions shall include, but not be limited to, being available to meet with counsel to prepare for discovery or trial and to act as a witness on behalf of the Company or any of its subsidiaries at mutually convenient times.  During and after Executive’s employment, Executive also shall cooperate fully with the Company and its subsidiaries in connection with any investigation or review of any federal, state or local regulatory authority as any such investigation or review relates to events or occurrences that transpired while Executive was employed by the Company, provided that Executive will not have any obligation under this paragraph with respect to any claim in which Executive has filed directly against the Company or related persons or entities or the Company has filed directly against Executive.  The Company shall reimburse Executive for any reasonable out-of-pocket expenses incurred by Executive in connection with Executive’s performance of Executive’s obligations pursuant to this Section 8(b).
7

Section 9.                      Section 409A . This Agreement is intended to comply with, or be exempt from, Code Section 409A (to the extent applicable) and the parties hereto agree to interpret this Agreement in the least restrictive manner consistent therewith.  Without limiting the generality of the foregoing, severance pay pursuant to Sections 7(d) or 7(e) constitute separate payments for purposes of Section 1.409A-2(b)(2) of the Treasury Regulations and thus, to the extent of payments made from the date of termination of Executive’s employment through March 15 of the calendar year following such termination, such payments are intended to constitute “short-term deferral” under Section 1.409A-1(b)(4) of the Treasury Regulations.  To the extent that severance payments or benefits are made following said March 15, they are intended to be payable upon an “involuntary separation from service” pursuant to Section 1.409A-1(b)(9)(iii) of the Treasury Regulations, to the maximum extent permitted by said provision.  Notwithstanding any other provisions of this Agreement to the contrary, if Executive is a “specified employee” within the meaning of Code Section 409A and the regulations issued thereunder, and a payment or benefit provided for in this Agreement or otherwise would be subject to additional tax under Code Section 409A if such payment or benefit is paid within six (6) months after Executive’s “separation from service” (within the meaning of Code Section 409A), then such payment or benefit shall not be paid (or commence) during the six-month period immediately following Executive’s separation from service except as provided in the immediately following sentence.  In such an event, any payments or benefits that would otherwise have been made or provided during such six-month period and which would have incurred such additional tax under Code Section 409A shall instead be paid to Executive in a lump-sum cash payment on the earlier of (i) the first regular payroll date of the seventh month following Executive’s separation from service or (ii) the 10th business day following Executive’s death (but not earlier than such payments otherwise would have been made).  In addition, no reimbursement or in-kind benefit shall be subject to liquidation or exchange for another benefit and the amount available for reimbursement, or in-kind benefits provided, during any calendar year shall not affect the amount available for reimbursement, or in-kind benefits to be provided, in a subsequent calendar year.  Any reimbursement to which Executive is entitled hereunder shall be made no later than the last day of the calendar year following the calendar year in which such expenses were incurred.  Notwithstanding anything herein to the contrary, neither the Company nor any of its affiliates shall have any liability to Executive or to any other person or entity if the payments and benefits provided in this Agreement that are intended to be exempt from or compliant with Code Section 409A are not so exempt or compliant.
 
Section 10.                    Parachute Payment .  In the event that (i) Executive becomes entitled to any payments or benefits hereunder or otherwise from the Company or any of its affiliates which constitute a “parachute payment” as defined in Code Section 280G (the “ Total Payments ”) and (ii) Executive is subject to an excise tax imposed under Code Section 4999 (the “ Excise Tax ”), then, if it would be economically advantageous for Executive, the Total Payments shall be reduced by an amount (including zero) that results in the receipt by Executive on an after tax basis (including the applicable federal, state and local income taxes, and the Excise Tax) of the greatest Total Payments, notwithstanding that some or all of the portion of the Total Payments may be subject to the Excise Tax.  All calculations hereunder shall be performed by a nationally recognized independent accounting firm selected by the Company, with the full cost of such firm being borne by the Company.  Any determinations made by such firm shall be final and binding on Executive and the Company.
8

Section 11.                    Clawback .  Notwithstanding anything herein to the contrary, any equity-based or incentive compensation provided to Executive, including any bonuses or equity awards provided pursuant to Sections 4(b) or 4(c) of this Agreement, shall be subject to any “clawback” required by law or by any national securities exchange on which the Company’s securities are listed, or to any clawback or recoupment policy otherwise adopted by the Company from time to time.  For the avoidance of doubt, notwithstanding anything herein to the contrary, in no event shall any reduction in the amount of compensation ultimately provided to or retained by Executive on account of this Section 11 constitute an event pursuant to which Executive may terminate employment for Good Reason or otherwise constitute a breach of this Agreement by the Company.
 
Section 12.                    No Conflict with Existing Obligations . Executive represents that Executive’s performance of all the terms of this Agreement and Executive’s duties as an executive of the Company do not and will not breach any agreement or obligation of any kind made prior to Executive’s employment by the Company, including agreements or obligations Executive may have with prior employers or entities for which Executive has provided services.  Executive has not entered into, and Executive agrees that Executive will not enter into, any agreement or obligation, either written or oral, in conflict herewith.
 
Section 13.                    Assignment . This Agreement for personal services shall not be assigned by Executive.  This Agreement will be binding upon and inure to the benefit of any successor of the Company.  Any such successor of the Company will be deemed substituted for the Company under the terms of this Agreement for all purposes.  For this purpose, “successor” means any person, firm, corporation or other business entity which at any time, whether by purchase, merger or otherwise, directly or indirectly acquires all or substantially all of the assets or business of the Company.
 
Section 14.                    Arbitration; WAIVER OF JURY TRIAL . In consideration of Executive’s employment with the Company, the Company and Executive agree that any and all controversies, claims, or disputes with anyone (including the Company, Executive and any executive, officer, director, shareholder or benefit plan of the Company in their capacity as such or otherwise) arising out of, relating to, or resulting from Executive’s employment with the Company or the termination of Executive’s employment with the Company, including any relating to this Agreement, will be subject to binding arbitration.  Disputes which Executive and Company hereby agree to arbitrate, AND THEREBY AGREE TO WAIVE ANY RIGHT TO A TRIAL BY JURY , include, but are not limited to, any statutory claims under state or federal law, including, but not limited to, claims under Title VII of the Civil Rights Act of 1964, the Americans with Disabilities Act of 1990, the Age Discrimination in Employment Act of 1967, the Older Workers Benefit Protection Act, the Worker Adjustment and Retraining Notification Act, the Family and Medical Leave Act, the New Jersey Law Against Discrimination, the New Jersey Conscientious Executive Protection Act, the New Jersey Family Leave Act, and any other federal, state or local discrimination, retaliation or wrongful termination claims or other statutory or common law claims.  Executive further understands that this agreement to arbitrate also applies to any disputes that the Company may have with Executive.  Executive and Company agree that any arbitration will be administered by the American Arbitration Association (“AAA”) and that a single neutral arbitrator will be selected in a manner consistent with its National Rules for the Resolution of Employment Disputes (the “Rules”).  All arbitration fees and costs shall be shared equally by the parties, but the parties shall be responsible for payment of their own attorneys’ and professional fees.  Executive and Company agree that the arbitrator will administer and conduct any arbitration in a manner consistent with the Rules.  Notwithstanding the foregoing, nothing herein shall limit or alter the Company’s right to seek injunctive or other equitable relief in any court of competent jurisdiction under (and as described in) the Confidentiality and Invention Assignment Agreement.
9

Section 15.                    Voluntary Nature of Agreement . Executive acknowledges and agrees that Executive is executing this Agreement voluntarily and without any duress or undue influence by the Company or anyone else.  Executive further acknowledges and agrees that Executive has carefully read this Agreement and that Executive has asked any questions needed for Executive to understand the terms, consequences and binding effect of this Agreement and fully understands it, including that Executive is WAIVING EXECUTIVE’S RIGHT TO A JURY TRIAL .  Finally, Executive agrees that Executive has been provided an opportunity to seek the advice of an attorney of Executive’s choice before signing this Agreement.
 
Section 16.                    Other .
 
(a)            Waiver of Breach . The waiver by the Company of a breach by Executive of any provision of this Agreement or the Confidentiality and Invention Assignment Agreement shall not operate or be construed as a waiver of the Company’s rights with respect to any subsequent breach by the Executive.  Any waiver of any provision of this Agreement must be in writing and signed by the waiving party.
 
(b)            Governing Law . This Agreement shall be construed and administered in accordance with the laws of the State of New Jersey, exclusive of its conflict of laws rules, and the parties hereto agree and stipulate that this Agreement shall be deemed to have been entered into in the State of New Jersey, regardless of where it was negotiated, implemented and/or executed.
 
(c)            Severability . In the event that any one or more of the provisions of this Agreement shall for any reason be held to be invalid, illegal, or unenforceable, the remaining provisions of this Agreement shall be unimpaired, and shall continue in full force and effect.
 
(d)            Construction . This Agreement shall be interpreted in accordance with its plain meaning, and the rule that ambiguities shall be construed against the drafter of the document shall not apply in connection with the construction or interpretation hereof.
 
(e)            Counterparts . This Agreement may be executed in two or more counterparts, each of which shall be deemed to be an original, but all of which together shall constitute one and the same instrument.
 
(f)             Entire Agreement . This Agreement and the Confidentiality and Invention Assignment Agreement contain the entire agreement and understanding of the parties with respect to the subject matter hereof, and supersede all prior or contemporaneous promises, understandings, or agreements, whether written or oral, relating to the subject matter hereof.  This Agreement may not be changed orally, but only by an agreement in writing, signed by both parties.
 
(g)            Survivorship .  The provisions of Sections 1, 7(d), 7(e) and 7(g) and Sections 8 through 16 shall survive the termination of Executive’s employment with the Company and this Agreement.
 
 
[Remainder of Page Intentionally Left Blank]
10

IN WITNESS WHEREOF, each of the parties has executed this Agreement, in the case of the Company by its duly authorized officer, as of the day and year first above written.

     
EDGE THERAPEUTICS, INC.
         
         
Date:
October 31, 2017   /s/ Brian Leuthner 
     
By:
Brian Leuthner
     
Title:
President and Chief Executive Officer
         
         
     
EXECUTIVE
         
         
Date:
October 31, 2017   /s/ Andrew Saik
     
Andrew Saik 


11

EXHIBIT A
 
CONFIDENTIALITY AND INVENTION ASSIGNMENT AGREEMENT
 
 
 
12


EXHIBIT B

Outside Activities

NONE
 
 
 
13

Exhibit 99.1
 
 
Edge Therapeutics Reports Third Quarter 2017 Financial Results

Appoints Pharmaceutical Industry Veteran Andrew Saik as Chief Financial Officer
 
BERKELEY HEIGHTS, N.J., November 1, 2017  — Edge Therapeutics ® , Inc. (Nasdaq: EDGE), a clinical-stage biotechnology company developing novel hospital-based therapies for the management of acute, life-threatening conditions, today announced financial and operational results for the quarter ended September 30, 2017, and recent corporate progress.
 
Third Quarter and Recent Corporate Progress
 
·
In September, the 150th patient was randomized into Edge’s EG-1962 Phase 3 NEWTON 2 study in aneurysmal subarachnoid hemorrhage (aSAH). The achievement of this milestone triggered preparation for a pre-specified futility analysis by the study’s external independent Data Monitoring Committee (DMC). Once the first 150 patients in the NEWTON 2 study complete their Day 90 follow-up assessments, the clinical data package will be compiled and submitted to the study’s DMC to perform the futility analysis.
·
Edge presented new retrospective, claims-based health economic data showing aSAH per patient hospital charges represent a high economic burden for U.S. hospitals. The analysis also showed that the aSAH patient population currently being studied in the NEWTON 2 study had the highest per patient hospital charges and experienced the longest hospitalizations among all aSAH patients. Specifically, these are patients who require an external ventricular drain (EVD), and undergo either neurosurgical clipping or endovascular coiling for repair of their aneurysm. The analysis was presented at the Neurocritical Care Society (NCS) 15th Annual Meeting.
·
Edge was announced as one of three finalists for the “Innovator of the Year” award for EG-1962 during the 2017 Congress of Neurological Surgeons (CNS) Annual Meeting. The finalists for the award, honoring the most innovative approaches considered to have the greatest impact on neurological surgery, were evaluated and selected by CNS’s membership of neurosurgeons.
·
Pharmaceutical industry leader Rosemary A. (Rose) Crane was appointed to Edge’s Board of Directors. The former executive at Johnson & Johnson and Bristol-Myers Squibb brings over 30 years of commercial and operations experience to the Board of Directors.
 
“We continued to achieve meaningful progress in the third quarter, highlighted by the randomization of the 150th patient in our Phase 3 NEWTON 2 study of EG-1962, and the presentation of new health economic data that quantify the tremendous health economic burden of aSAH,” said Brian A. Leuthner, Edge’s President and Chief Executive Officer. “The health economic analysis reinforces our commitment to evaluating EG-1962 as a potential treatment option for patients with aSAH. Our top priority is executing on the ongoing Phase 3 study and we remain on track for conducting the pre-specified futility analysis by the end of 2017. We anticipate reporting top-line efficacy results from the formal interim analysis in early 2018. If the study continues to full enrollment as planned, we anticipate providing top-line results from the full study in late 2018.”
1

Financial Results
 
Cash Position: Cash, cash equivalents and marketable securities as of September 30, 2017 were $97.3 million, compared with $106.4 million as of December 31, 2016.
 
Research & Development (R&D) Expenses:   R&D expenses were $6.9 million in the third quarter of 2017, compared to $6.7 million in the third quarter of 2016. The increase in R&D expense was primarily due to an increase in external expenses related to EG-1962 clinical development, personnel-related costs related to the NEWTON 2 study and other R&D expenses.
 
General & Administrative (G&A) Expenses: G&A expenses were $4.0 million for the three months ended September 30, 2017, compared to $3.6 million in the comparable period in 2016. The increase in G&A expense was largely due to increases in personnel-related costs, legal and professional fees.
 
Net Loss: Net loss was $11.3 million for the third quarter ended September 30, 2017, compared to net loss of $10.8 million for the comparable period in 2016.
 
Appoints Andrew Saik as Chief Financial Officer and Makes Inducement Grant under NASDAQ Rule 5635(c)(4)
 
Additionally, Edge announced the appointment of Andrew Saik as the company’s Chief Financial Officer, effective immediately. Mr. Saik will be responsible for leading financial strategy and operations for Edge, and will report to Mr. Leuthner. Mr. Saik was most recently Chief Financial Officer at Vertice Pharma, LLC, where he secured a $300 million commitment to fund acquisitions from a prominent private equity firm. Previously, he was Chief Financial Officer at Auxilium Pharmaceuticals, Inc., where he helped lead the execution of Auxilium’s growth strategy and successful sale to Endo International plc for $2.3 billion. He succeeds Albert N. Marchio II, Edge’s Chief Accounting and Administrative Officer, who became Edge’s CFO on an interim basis when the company’s previous CFO left in March 2017. Mr. Marchio will help with the transition of the new CFO and will continue to serve as Edge’s Chief Accounting and Administrative Officer.
 
Mr. Saik was previously Senior Vice President, Finance and Treasurer at Endo Health Solutions, Inc., where he was responsible for internal and external reporting, global consolidations of M&A transactions, cash management, debt financing and risk management. During his tenure at Endo, he helped complete the $1.6 billion acquisition of Paladin Labs and refinance $3 billion in debt in a new corporate structure. Prior to Endo, Mr. Saik served in senior financial management roles with increasing responsibility at Valeant Pharmaceuticals International, including Senior Vice President, Finance. In this post, he served as the overall finance lead for the acquisition and integration of the Johnson & Johnson and Sanofi-Aventis dermatology business units in the U.S. and Canada, enabling Valeant to build the largest dermatology business in North America. Previously at Valeant, Mr. Saik was Chief Financial Officer of the $1.5 billion Specialty Pharmaceuticals Division. He holds a Master of Business Administration from the University of Southern California and a Bachelor of Arts from the University of California, Los Angeles.
 
“After an extensive search, we’ve selected a proven finance executive in the pharmaceutical industry with a track record of success in multiple areas including shaping financial strategy, leading successful M&A transactions, integrating global company and product acquisitions and cash management that have helped add significantly to shareholder value,” said Mr. Leuthner. “We believe Andrew further strengthens Edge’s management team as the company moves toward potential commercialization of EG-1962. I also want to acknowledge Bert Marchio, who has done an exceptional job since stepping in to fill the CFO role in March.”
2

“This is an exciting time to join the Edge team, which has achieved impressive progress so far with its EG-1962 development program and expects to reach key milestones during the balance of 2017 and in 2018,” said Mr. Saik. “As the company continues clinical development of EG-1962 for patients with aSAH, I look forward to contributing to the company’s future success and helping Edge to maintain a strong financial position so that we are ready for potential commercialization.”
 
In connection with Mr. Saik’s new employment, the Compensation Committee of Edge’s Board of Directors has approved the grant of non-qualified stock options to Mr. Saik, who will receive options to purchase 200,000 shares of Edge’s common stock. The effective date of the grant is November 1, 2017 and the exercise price for such stock options will be equal to the closing price of Edge’s common stock on such date, as reported by NASDAQ. The grant was made as an inducement material to Mr. Saik’s acceptance of employment with Edge, in accordance with NASDAQ Listing Rule 5635(c)(4).
 
The options have a 10-year term and will vest over a period of four years, with 25 percent vesting on October 31, 2018, which is one year following Mr. Saik’s date of hire, and the remaining 75 percent vesting in approximately equal monthly increments over the succeeding thirty-six months, subject to Mr. Saik’s continuous employment with Edge through each applicable vesting date. In addition, the options are subject to acceleration or forfeiture upon the occurrence of certain events as set forth in Mr. Saik’s option and employment agreements.
 
Conference Call Details
 
Edge will host a conference call and webcast today, Wednesday, November 1, 2017 at 8:30 a.m. EDT. Please dial (877) 388-5691, or (562) 350-0788 for international callers, and reference participant code 95430949 approximately 15 minutes prior to the call. A replay of the call may be accessed through November 15, 2017 on the investor section of Edge’s website or by dialing (855) 859-2056, or (404) 537-3406 for international callers, and referencing participant code 95430949. A live webcast of the conference call will be available on the investor relations section of Edge’s website at www.edgetherapeutics.com .
3

About Edge Therapeutics, Inc.
 
Edge Therapeutics, Inc. is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies capable of transforming treatment paradigms for the management of acute, life-threatening neurological and other conditions. EG-1962, Edge’s lead product candidate, has the potential to fundamentally improve patient outcomes and transform the management of aneurysmal subarachnoid hemorrhage, which is bleeding around the brain due to a ruptured brain aneurysm. Edge is evaluating EG-1962 in two clinical studies: a pivotal Phase 3 NEWTON 2 study of EG-1962 delivered via external ventricular drain, and a study of direct intracisternal administration of EG-1962. For additional information about Edge, please visit www.edgetherapeutics.com .

Forward-Looking Statements
 
This press release and any statements of representatives of Edge Therapeutics, Inc. related thereto that are not historical in nature contain, or may contain, among other things, certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, without limitation, statements with respect to Edge’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “seeks,” “intends,” “plans,” “potential” or similar expressions, including statements with respect to the potential effects of its products, the results of NEWTON 2 potentially supporting registration for EG-1962 throughout the world, the pre-planned futility analysis in late 2017, top-line efficacy results from the interim analysis in early 2018 and, if needed, top-line results from the full study in late 2018. These statements are based upon the current beliefs and expectations of Edge’s management and are subject to significant risks and uncertainties. Actual results may differ significantly from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various risk factors (many of which are beyond Edge’s control) as described under the heading “Risk Factors” in Edge’s filings with the United States Securities and Exchange Commission.

###

Investor and Media Contact:
Gregory Gin
Edge Therapeutics, Inc.
Tel: 1-800-208-EDGE (3343)
Email: ir@edgetherapeutics.com
 
4

EDGE THERAPEUTICS, INC.
Statements of Operations and Comprehensive Loss
(Unaudited)
 
 
 
Three Months Ended
September 30,
   
Nine Months Ended
September 30,
 
 
 
2017
   
2016
   
2017
   
2016
 
Operating expenses:
                       
Research and development expenses
 
$
6,913,171
   
$
6,724,503
   
$
23,477,971
   
$
18,046,572
 
General and administrative expenses
   
3,990,283
     
3,552,289
     
12,365,509
     
10,526,775
 
 
                               
Total operating expenses
   
10,903,454
     
10,276,792
     
35,843,480
     
28,573,347
 
 
                               
Loss from operations
   
(10,903,454
)
   
(10,276,792
)
   
(35,843,480
)
   
(28,573,347
)
 
                               
Other income (expense):
                               
Other expense
   
-
     
(163,463
)
   
-
     
(163,463
)
Interest income
   
214,064
     
56,082
     
479,297
     
148,272
 
Interest expense
   
(592,089
)
   
(375,089
)
   
(1,591,998
)
   
(717,263
)
 
                               
Net loss and comprehensive loss
   
(11,281,479
)
   
(10,759,262
)
   
(36,956,181
)
   
(29,305,801
)
 
                               
Loss per share basic and diluted
 
$
(0.37
)
 
$
(0.37
)
 
$
(1.23
)
 
$
(1.02
)
 
                               
Weighted average common shares outstanding basic and diluted
   
30,852,514
     
28,896,941
     
30,091,640
     
28,848,842
 
 
5

EDGE THERAPEUTICS, INC.
Balance Sheets
 
 
 
September 30, 2017
   
December 31, 2016
 
ASSETS
 
(unaudited)
       
Current assets:
           
Cash and cash equivalents
 
$
97,307,258
   
$
106,398,919
 
Prepaid expenses and other current assets
   
326,733
     
954,581
 
Total current assets
   
97,633,991
     
107,353,500
 
 
               
Property and equipment, net
   
3,462,343
     
3,418,077
 
Other assets
   
142,870
     
142,870
 
 
               
Total assets
 
$
101,239,204
   
$
110,914,447
 
 
               
LIABILITIES AND STOCKHOLDERS’ EQUITY
               
LIABILITIES
               
Current liabilities:
               
Accounts payable
 
$
2,964,971
   
$
3,471,032
 
Accrued expenses
   
3,282,398
     
3,213,715
 
Short term debt
   
5,454,610
     
-
 
Total current liabilities
   
11,701,979
     
6,684,747
 
 
               
Noncurrent liability:
               
Long term debt
   
14,883,240
     
14,953,143
 
 
               
STOCKHOLDERS’ EQUITY
               
Preferred stock, 5,000,000  shares authorized at September 30, 2017 and December 31, 2016, 0 outstanding
   
-
     
-
 
Common stock, $0.00033 par value, 75,000,000 shares authorized at September 30, 2017 and December 31, 2016, 30,859,200 shares and 28,918,516 shares issued and outstanding at September 30, 2017 and  December 31, 2016, respectively
   
10,397
     
9,756
 
Additional paid-in capital
   
212,688,325
     
190,341,769
 
Accumulated deficit
   
(138,044,737
)
   
(101,074,968
)
Total stockholders’ equity
   
74,653,985
     
89,276,557
 
 
               
Total liabilities and stockholders’ equity
 
$
101,239,204
   
$
110,914,447
 


6